Enliven Therapeutics, Inc.
ELVN
$58.82
$0.761.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.22% | 17.23% | -27.99% | 12.99% | -26.99% |
| Total Depreciation and Amortization | -91.36% | -81.08% | -42.50% | -22.50% | 3.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.58% | 13.41% | 96.10% | 18.13% | 106.33% |
| Change in Net Operating Assets | -293.29% | -37.58% | 339.02% | -103.15% | 107.14% |
| Cash from Operations | -8.64% | 20.04% | 7.93% | -8.91% | 16.53% |
| Capital Expenditure | 28.78% | -- | -- | 104.55% | -6,850.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -140.65% | 2,838.91% | 1,573.45% | -127.34% | -444.96% |
| Cash from Investing | -140.52% | 2,880.10% | 1,602.75% | -127.37% | -445.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 112.21% | 4,196.15% | -98.20% | -- | 11,991.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 112.21% | 4,196.15% | -98.44% | -132.95% | 11,991.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.27% | 248.17% | -112.07% | -572.13% | 133.91% |